Pliant Therapeutics, Inc. (PLRX)

13.98 +0.73 (+5.51%) At close: 04:00PM EDT

Pliant Therapeutics, Inc.

260 Littlefield Avenue
South San Francisco, CA 94080
United States
650 481 6770
https://pliantrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 158

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Bernard Coulie M.B.A., M.D., Ph.D.	President, CEO & Director	1.06M	817.36k	1967
Dr. Keith Lamont Cummings M.B.A., M.D.	Chief Financial Officer	662.34k	69.48k	1977
Mr. Mike Ouimette J.D.	General Counsel & Corporate Secretary	591.05k	N/A	1973
Mr. Johannes P. Hull	Chief Business Officer	631.64k	N/A	1975
Dr. Éric Lefebvre M.D.	Chief Medical Officer	763.49k	N/A	1964
Dr. Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Dean Sheppard M.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Bill DeGrado Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Hal Chapman M.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Craig D. Muir	Interim Chief Technology Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Corporate governance

Pliant Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.